ArticleAnnals of the rheumatic diseases2020
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04667780 (Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19), which is not on this map. Cited by 96 papers, 17 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19
Who cites it
96 citing papers in PubMed, 17 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- The role of colchicine in the management of COVID-19: a Meta-analysis.BMC pulmonary medicine · 2024Pooled it
- Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Impact of colchicine on mortality and morbidity in COVID-19: a systematic review.Annals of medicine · 2022Pooled it
- Effect of colchicine on mortality in patients with COVID-19 - A systematic review and meta-analysis.Diabetes & metabolic syndrome · 2022Pooled it
- Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges.Global health, epidemiology and genomics · 2022Pooled it
- Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Einstein (Sao Paulo, Brazil) · 2022Pooled it
- Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials.PloS one · 2022Pooled it
- Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis.European journal of clinical investigation · 2021Pooled it
- Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression.International immunopharmacology · 2021Pooled it
- Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.Clinical and experimental pharmacology & physiology · 2021Pooled it
- Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19.The American journal of cardiology · 2021Pooled it
- Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.The European respiratory journal · 2021Guideline
- A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.Seminars in arthritis and rheumatism · 2021Pooled it
- Pooled it
- Pooled it
- Impact of colchicine on mortality in patients with COVID-19: A meta-analysis.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheoresePooled it
- The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis.International journal of immunopathology and pharmacologyPooled it
- The Efficacy of Colchicine as an Adjunct Therapy in Non-hospitalized COVID-19 Patients: A Randomized Placebo-Controlled Trial.Recent advances in anti-infective drug discovery · 2024Trial
- The effects of colchicine on hospitalized COVID-19 patients: A randomized, double-blind, placebo-controlled clinical trial.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2023Trial
- Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial.European journal of internal medicine · 2023Trial
36 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
28 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC).
methodsIn the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction).
resultsPatients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%)
conclusionThis proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.